Notes:
The thromboembolic events in control patients from three prospective trials (AFASAK, SPAF and BAATAF) are combined and classified as cerebral or systemic (non-CNS). Most thromboembolic events associated with atrial fibrillation involve the brain.

Note:
“Intention-to-treat” results are shown. Thromboembolic events represent all such events regardless of suspected etiology. Transient ischemic attacks and intracerebral hemorrhages are not included. Control represents placebo in all studies except BAATAF where 46% of the “control” patients received aspirin and 54% received no treatment. SPAF data are from group I only.

Back

Contents

Next

Acknowledgments:
The content of this presentation was prepared by Dr. Gregory Albers of the Stanford Stroke Center.